login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
AILERON THERAPEUTICS INC (ALRN) Stock News
USA
- NASDAQ:ALRN -
US00887A2042
-
Common Stock
2.11
USD
+0.18 (+9.33%)
Last: 1/10/2025, 8:00:59 PM
2.11
USD
0 (0%)
After Hours:
1/10/2025, 8:00:59 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ALRN Latest News, Press Relases and Analysis
All
Press Releases
9 months ago - By: Rein Therapeutics, Inc.
- Mentions:
RNTX
Aileron Therapeutics Announces Rebranding to Rein Therapeutics
11 months ago - By: Aileron Therapeutics, Inc.
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
11 months ago - By: Benzinga
Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis
a year ago - By: Aileron Therapeutics, Inc.
Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
a year ago - By: Aileron Therapeutics, Inc.
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma
a year ago - By: BusinessInsider
ALRN Stock Earnings: Aileron Therapeutics Misses EPS for Q2 2024
a year ago - By: InvestorPlace
ALRN Stock Earnings: Aileron Therapeutics Reported Results for Q1 2024
a year ago - By: BusinessInsider
ALRN Stock Earnings: Aileron Therapeutics Reported Results for Q1 2024
a year ago - By: Aileron Therapeutics, Inc.
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis
a year ago - By: Aileron Therapeutics, Inc.
Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
a year ago - By: Aileron Therapeutics, Inc.
Aileron Therapeutics to Present at the 8th Annual IPF Summit
a year ago - By: InvestorPlace
ALRN Stock Earnings: Aileron Therapeutics Misses EPS for Q2 2024
a year ago - By: Aileron Therapeutics, Inc.
Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
a year ago - By: InvestorPlace
ALRN Stock Earnings: Aileron Therapeutics Reported Results for Q4 2023
a year ago - By: Aileron Therapeutics, Inc.
Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
a year ago - By: Aileron Therapeutics, Inc.
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
a year ago - By: Aileron Therapeutics, Inc.
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
a year ago - By: Aileron Therapeutics, Inc.
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
a year ago - By: Aileron Therapeutics, Inc.
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
a year ago - By: Aileron Therapeutics, Inc.
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
a year ago - By: Aileron Therapeutics, Inc.
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
a year ago - By: Aileron Therapeutics, Inc.
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
a year ago - By: Aileron Therapeutics, Inc.
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
a year ago - By: Aileron Therapeutics, Inc.
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
a year ago - By: Aileron Therapeutics, Inc.
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
a year ago - By: Benzinga
- Mentions:
GENE
ME
BPTH
ICU
...
12 Health Care Stocks Moving In Thursday's Intraday Session
a year ago - By: Aileron Therapeutics, Inc.
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
a year ago - By: Aileron Therapeutics, Inc.
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2 years ago - By: Aileron Therapeutics, Inc.
Aileron Therapeutics Announces CEO Transition
2 years ago - By: Aileron Therapeutics, Inc.
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
2 years ago - By: Aileron Therapeutics, Inc.
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
2 years ago - By: Aileron Therapeutics, Inc.
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
2 years ago - By: Aileron Therapeutics, Inc.
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
2 years ago - By: Seeking Alpha
Aileron Therapeutics files to sell 7.06M shares for holders (NASDAQ:ALRN)
2 years ago - By: InvestorPlace
- Mentions:
VLCN
CRGE
AERT
JTAI
...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Please enable JavaScript to continue using this application.